紫杉醇联合放疗治疗中晚期乳腺癌的临床疗效及安全性评价

Clinical efficacy of paclitaxel combined with radiotherapy in the treatment of advanced breast cancer and safety evaluation

目的:观察紫杉醇联合放疗治疗中晚期乳腺癌的临床疗效,并进行安全性评价。方法:选择74例中晚期乳腺癌患者为研究对象,随机分为观察组和对照组,每组37例。观察组患者采取紫杉醇化疗联合放疗治疗,对照组单纯予以放疗治疗,共治疗2个疗程,观察两组患者生活质量改善情况、患者乳腺组织Bax和p53 mRNA表达水平、临床疗效以及不良反应发生率。结果:治疗后,观察组患者治疗总有效率高于对照组(χ~2=7.929,P=0.005);治疗后,观察组患者生活质量提高率为62.2%,高于对照组的18.9%(χ~2=14.352,P=0.000);治疗前,两组患者的乳腺组织Bax和p53 mRNA表达水平比较,差异均无统计学意义(P>0.05),治疗后,二者表达水平均有所升高(P<0.05),观察组患者Bax和p53 mRNA表达水平均高于对照组(P<0.05);观察组患者不良反应发生率为13.51%(5/37),对照组患者不良反应发生率为16.22%(6/37),两组患者不良反应发生率比较,差异无统计学意义(χ~2=0.107,P=0.743)。结论:紫杉醇同步放疗化疗治疗能够提高中晚期乳腺癌患者的治疗效果,提高患者生活质量,提高乳腺组织Bax和p53表达水平,且不良反应较少,值得推广应用。

Objective： To observe the clinical efficacy of paclitaxel combined with radiotherapy in the treatment of advanced breast cancer and evaluate the safety. Methods： 74 patients with advanced breast cancer were chosen and randomly divided into the observation group and the control group,37 cases in each group. The observation group wastreated with paclitaxel chemotherapy combined with radiotherapywhile the control group was treated with radiotherapy treatment for a total of 2 courses of treatment,with the improvement of life quality,expression levels of the tissue in patients with Bax and p53 mRNA,clinical efficacy and incidence of adverse reactions compared. Results： After treatment,the total efficiency rate of the observation group is higher than that of the control group（ χ~2= 7. 929,P = 0. 005）; the improvement rate of life quality in the observation group（ 62. 2 %） was higher than that of the control group（ 18. 9 %）（ χ~2= 14. 352,P = 0. 000）. Before treatment,there was no difference in the expression levels of Bax and p53 mRNA in breast tissue of the two groups（ P 〉 0. 05）. After treatment,the two expression levels were increased（ P 〈 0. 05）,and the expression levels of Bax and p53 mRNA in the observation group were higher than those of the control group（ P 〈 0. 05）;the incidence rates of adverse reaction in the observation group and the control group were 13. 51%（ 5/37） and 16. 22 %（ 6/37） respectively,there being no difference（ χ~2= 0. 107,P = 0. 743）. Conclusion： Paclitaxel concurrent radiotherapy and chemotherapy can improve the therapeutic efficacy for patients with advanced breast cancer,improve the quality of life and the expression levels of Bax and p53 in breast tissueand have less adverse reactions,worthy of popularization and application.